| NCT ID | NCT07749820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | BrosMed Medical Co., Ltd |
| Condition | Deep Vein Thrombosis (DVT) |
| Study Type | INTERVENTIONAL |
| Enrollment | 167 participants |
| Start Date | 2026-08-30 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 167 participants in total. It began in 2026-08-30 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study plans to enroll 167 subjects. Subject enrollment and treatment details will be documented, and follow-up assessments will be conducted at screening, on the procedure day, before discharge, and at 1, 3, and 6 months after the procedure, to assess the safety and efficacy of the peripheral thrombectomy system for the treatment of lower extremity deep vein thrombosis.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years； * Confirmed lower extremity deep vein thrombosis (DVT) by imaging, meeting at least one of the following: (1) acute iliofemoral or femoropopliteal DVT; or (2) subacute iliofemoral DVT; * Investigator-assessed life expectancy ≥1 year; * Willing to participate in this study and provide written informed consent. Exclusion Criteria: * Infection at the puncture site or severe systemic infection; * Inability to establish vascular access or difficulty in advancing the guidewire through the lesion; * Hemodynamically unstable pulmonary embolism; * The target lesion thrombosis is recurrent after prior interventional therapy; * A venous stent has been implanted in the target lesion, or the presence of an inferior vena cava filter that interferes with device deployment; * Bilateral lower extremity deep vein thrombosis requiring thrombectomy in the same procedure; * Active bleeding within the past 30 days, including severe intracranial, gastrointestinal, or urinary tract bleeding; * History of hemorrhagic or ischemic stroke within the past 30 days; * Known severe coagulation disorder or bleeding tendency; * Severe hepatic or renal impairment; * Known allergy or significant hypersensitivity to iodine-based contrast media, thrombolytic agents, anticoagulants, or antiplatelet drugs; * Known conditions such as severe hyperthyroidism, multiple myeloma, or severe heart failure that preclude tolerance to percutaneous transluminal angioplasty; * Pregnant or lactating women, or women planning to become pregnant during the study period; * Currently participating in any other clinical trial of a drug or medical device; * Any other condition that, in the investigator's judgment, makes the subject ineligible for participation in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07749820 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Deep Vein Thrombosis (DVT). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07749820 currently recruiting?
Yes, NCT07749820 is actively recruiting participants. Contact the research team at fu.weiguo@zs-hospital.sh.cn for enrollment information.
Where is the NCT07749820 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07749820 clinical trial?
NCT07749820 is sponsored by BrosMed Medical Co., Ltd. The trial plans to enroll 167 participants.